Skip to main content

Table 1 The following antibodies were used

From: SRT3025-loaded cell membrane hybrid liposomes (3025@ML) enhanced anti-tumor activity of Oxaliplatin via inhibiting pyruvate kinase M2 and fatty acid synthase

Antibody

Company

Catalog no.

Dilution

Anti Pyruvate kinase M2

(PKM2)

Cell Signaling Technology, Danvers, MA, USA

4053

1000 ×

Anti BCL2-Associated X

(Bax)

Abcam, Cambridge, UK

ab32503

1000 ×

Anti B-cell lymphoma-2

(Bcl-2)

Abcam

ab32124

1000 ×

Anti Cleaved Caspase-3

Cell Signaling Technology

9661

1000 ×

Anti fatty acid synthase

(FASN)

Cell Signaling Technology

3180

1000 ×

Anti- PI3 Kinase p110 Beta

(p-PI3K)

Abcam

ab151549

1000×

Anti phospho-protein kinase B

(p-AKT)

Cell Signaling Technology

9271 S

1000×

Anti phospho-mammalian target of rapamycin

(anti p-mTOR)

Abcam

ab109268

1000×

Anti β-Actin

Sigma-Aldrich, St. Louis, USA

A3854

50,000×